Borrelia burgdorferi strain 257

US5434077A · kind A · utility

Assignees

• Max-Planck-Gesellschaft zur Föderung der Wissenschaften e.V. · US
• DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS · DE

Inventors

• Markus Simon · Buckenhof, DE
• Ulrich E. Schaible · Freiberg, DE
• Klaus Eichmann · Glückstadt, DE
• Michael Kramer · Freiberg, DE
• Wallich Reinhard · Heidelberg, DE

Key dates

• Filing date: May 27, 1993
• Grant date: Jul 18, 1995
• Expiry date: May 27, 2013

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides a vaccine against Lyme disease, wherein it contains one or more monoclonal antibodies which are specific for the 31 kD antigen (OspA) or the 34 kD antigen (OspB) of Borrelia burgdorferi. The present invention also provides a process for obtaining this vaccine, as well as new monoclonal antibodies and antigens.